前列腺癌复发

预约门诊

生存率

前列腺癌复发大多以生化复发开始。也就是说，PSA 水平升高，但影像学检查未见任何癌症病灶。得知癌症复发可能令人痛苦，而且您可能想知道复发对您的未来意味着什么。

生化复发会增加前列腺癌扩散或导致死亡的风险，但这些结局并不一定发生。如果生化复发后发生转移，平均时间是 7 至 8 年后出现。曾有研究对前列腺切除术后出现生化复发的患者进行随访，发现半数患者死于前列腺癌的时间点在术后 16 年以上。许多人在前列腺癌复发后还能存活多年。

如果癌症扩散到身体其他部位，可能更难控制。如果出现以下情况，患转移性前列腺癌的风险更高：

  • PSA 水平快速升高。 医疗护理专业人员经常为前列腺癌复发患者测量 PSA 水平倍增的时间。即 PSA 水平升高 1 倍所需的时间。如果倍增时间少于 12 个月，则提示转移风险较高。
  • 首次确诊时格利森评分较高。 格利森评分是一个数字，可以让医护团队了解癌细胞与健康前列腺细胞的形态差异程度。对于前列腺癌首次确诊时格利森评分为 8 至 10 分的患者，其转移风险高于评分较低的患者。
  • 复发时 PSA 水平较高。 对于接受前列腺切除术治疗的患者，PSA 水平高于 0.5 纳克/毫升（ng/mL）说明转移风险较高。
  • 复发距离治疗的时间较短。 对于接受放射疗法治疗的患者，在治疗后 18 个月内复发会增加转移风险。

如果癌症扩散，有许多治疗方法可以帮助控制。但转移性前列腺癌通常无法治愈。癌症扩散后的 5 年生存率约为 38%。也就是说，在每 100 个转移性前列腺癌患者中，约有 38 人预计可在确诊后存活 5 年。

该生存率来源于针对 5 年多前接受前列腺癌治疗的患者研究数据。这些患者可能没有获得过可以帮助延长转移性前列腺癌患者生存期的最新治疗。有临床试验正在研究新疗法和使用现有疗法的新方式。

向医护团队咨询预后以及可能影响个人预后的因素。

申请预约
诊断与治疗医生与科室
May 14, 2026
  1. Lee WR. Rising serum PSA following local therapy for prostate cancer: Definition, natural history and risk stratification. https://www.uptodate.com/contents/search. Accessed Sept. 22, 2025.
  2. Dmochowski RR, et al., eds. Campbell-Walsh-Wein Urology. 13th ed. Elsevier; 2026. https://www.clinicalkey.com. Accessed Sept. 22, 2025.
  3. Penson DF. Follow-up surveillance after definitive local treatment for prostate cancer. https://www.uptodate.com/contents/search. Accessed Sept. 22, 2025.
  4. Cornford P, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: Treatment of relapsing and metastatic prostate cancer. European Urology. 2021; doi:10.1016/j.eururo.2020.09.046.
  5. Westphalen AC, et al. Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation. https://www.uptodate.com/contents/search. Accessed Sept. 22, 2025.
  6. Advanced prostate cancer patient guide. Urology Care Foundation. https://www.urologyhealth.org/educational-resources/advanced-prostate-cancer. Accessed Sept. 22, 2025.
  7. Taplin ME, et al. Clinical presentation and diagnosis of prostate cancer. https://www.clinicalkey.com. Accessed Oct. 1, 2025.
  8. Cackowski FC, et al. Prostate cancer dormancy and recurrence. Cancer Letters. 2022; doi:10.1016/j.canlet.2021.09.037.
  9. Prostate cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1459. Accessed Sept. 23, 2025.
  10. Survivorship. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1466. Accessed Sept. 25, 2025.
  11. Rock CL, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA: A Cancer Journal for Clinicians. 2022; doi:10.3322/caac.21719.
  12. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline (2024). American Urological Association. https://www.auanet.org/guidelines-and-quality/guidelines/salvage-therapy-for-prostate-cancer. Accessed Sept. 22, 2025.
  13. Lee WR. Rising or persistently elevated serum PSA following radical prostatectomy: Management. https://www.uptodate.com/contents/search. Accessed Sept. 22, 2025.
  14. Richie JP. Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy. https://www.uptodate.com/contents/search. Accessed Sept. 22, 2025.
  15. Salvage. Dorland's Medical Dictionary Online. https://www.dorlandsonline.com. Accessed Sept. 25, 2025.
  16. Van den Broeck T, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. European Urology. 2019; doi:10.1016/j.eururo.2018.10.011.
  17. Freedland SJ, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; doi:10.1001/jama.294.4.433.
  18. Cancer stat facts: Prostate cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/prost.html. Accessed Sept. 30, 2025.
  19. Choline C 11 injection (approval letter). New Drug Application 203155. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203155. Accessed April 4, 2025.
  20. Harris KM. Allscripts EPSi. Mayo Clinic. April 23, 2024.
  21. Become a comprehensive radiopharmaceutical therapy center of excellence. Society of Nuclear Medicine and Molecular Imaging. https://snmmi.org/Web/Clinical-Practice/Radiopharmaceutical-Therapy-Centers-of-Excellence/Become-a-Comprehensive-Radiopharmaceutical-Therapy-Center-of-Excellence.aspx. Accessed July 29, 2025.
  22. Medical review (expert opinion). Mayo Clinic. Nov. 10, 2025.

相关

相关医疗程序

前列腺癌复发